Press release
Niemann-Pick Disease Type C (NPC) Market Redefines Rare Disease Care with Emerging Treatment Strategies | United States Growth Expansion
Niemann-Pick Disease Type C (NPC) Market Size 2026-2035
DataM Intelligence has released its latest "Niemann-Pick Disease Type C (NPC) Market Size 2026" report, delivering comprehensive insights into market trends, growth opportunities, competitive dynamics, and regional performance. The report covers market size by value and volume, CAGR forecasts, and emerging opportunities, the report delivers data-driven insights into industry developments, competitive trends, and future market outlook, enabling more effective strategic planning and market expansion.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/niemann-pick-disease-type-c-market?kb
United States: Recent Industry Developments
✅ June 2026: Zevra Therapeutics announced publication of positive MIPLYFFA® (arimoclomol) Phase 2/3 pediatric substudy data, demonstrating favorable safety and tolerability in infants with Niemann-Pick Disease Type C (NPC).
✅ May 2026: GeneDx partnered with Zevra Therapeutics to expand sponsored genetic testing for suspected NPC patients, improving access to earlier diagnosis through exome sequencing.
✅ April 2026: Zevra Therapeutics continued expanding the U.S. commercial rollout of MIPLYFFA®, strengthening patient access programs and increasing physician adoption following its FDA approval.
✅ March 2026: Zevra Therapeutics advanced its global Expanded Access Program for arimoclomol while supporting broader treatment availability for eligible NPC patients.
Find the right strategic partners to accelerate your business. Get started today:- https://www.datamintelligence.com/partner-identification-enquiry/niemann-pick-disease-type-c-market?kb
Top List of Key Player:
Zevra Therapeutics., IntraBio., Johnson & Johnson Services, Inc., Emerging Market Players, Cyclo Therapeutics, Inc, Azafaros B.V.
Key Industry Developments 2026:
In June 2026, Zevra Therapeutics, Inc. announced the publication of positive MIPLYFFA® (arimoclomol) Phase 2/3 pediatric substudy results, demonstrating favorable safety and tolerability in infants with Niemann-Pick Disease Type C (NPC).
In June 2026, Cyclo Therapeutics, Inc. announced that the final patient completed the last visit in its pivotal Phase 3 TransportNPCTM trial evaluating Trappsol® CycloTM for Niemann-Pick Disease Type C, with topline results expected in the second half of 2026.
In February 2026, Zevra Therapeutics, Inc. presented new real-world and clinical data for MIPLYFFA® at the 22nd Annual WORLDSymposiumTM, highlighting long-term safety and effectiveness in pediatric and adult patients with Niemann-Pick Disease Type C.
In January 2026, IntraBio Inc. received European Commission marketing authorization for AQNEURSA® (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Disease Type C, expanding treatment options for patients across Europe.
Growth Forecast Projection 2026:
The Global Niemann-Pick Disease Type C (NPC) Market is expected to witness significant growth during the forecast period 2026-2035. In 2025, the market is projected to accelerate as leading players continue to implement strategic initiatives that drive adoption. This sustained growth is set to create emerging opportunities and enhance long-term revenue potential across the industry.
How Our Market Research Process Works 2026-2035:
The Niemann-Pick Disease Type C (NPC) Market report by DataM Intelligence delivers comprehensive insights backed by extensive primary and secondary research. It analyzes key market trends, competitive dynamics, regulatory developments, technological advancements, emerging innovations, and growth opportunities while highlighting potential challenges and evolving market conditions. The report provides actionable intelligence to support strategic planning and identify future market potential.
Latest M & A/ partnerships in 2026:
• February 2026: THX Pharma (Theranexus) granted Biocodex an exclusive license for the development and commercialization of TX01 for Niemann-Pick Disease Type C in the U.S. and Canada.
Buy Now & Unlock 360° Complete Market Insights: https://www.datamintelligence.com/buy-now-page?report=niemann-pick-disease-type-c-market?kb
Japan: Recent Industry Developments
✅ June 2026: Takeda Pharmaceutical Company Limited continued supporting research collaborations focused on rare genetic and lysosomal storage disorders, including initiatives relevant to NPC diagnosis and treatment.
✅ May 2026: Sysmex Corporation expanded its advanced genetic and molecular diagnostic capabilities, supporting earlier identification of rare inherited metabolic disorders such as Niemann-Pick Disease Type C.
✅ March 2026: Shionogi & Co., Ltd. strengthened investment in rare disease research through collaborations aimed at accelerating innovative therapies for underserved patient populations.
✅ February 2026: Japanese academic hospitals and rare disease networks expanded participation in international registries and natural history studies for Niemann-Pick Disease Type C, supporting future clinical research and patient management.
Key Segmentation Plannings (2026):
By Drug: Arimoclomol (MIPLYFFA), Levacetylleucine (AQNEURSA), Miglustat
By Patient Type: Adult, Pediatric
Global Market Growth Regional Analysis:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1 - Market Overview: Provides a comprehensive introduction to the Niemann-Pick Disease Type C (NPC) Market, including key segments by region, product type, and application, along with market size, growth potential, and short- and long-term outlook.
Chapter 2 - Emerging Trends: Highlights the latest industry trends, technological advancements, and innovations driving market transformation.
Chapter 3 - Competitive Landscape: Analyzes the competitive environment, including market share, strategic developments, partnerships, and recent mergers and acquisitions.
Chapter 4 - Leading Company Profiles: Presents detailed profiles of major market participants, covering revenue, product portfolios, operating performance, and recent developments.
Chapters 5 & 6 - Regional and Country Analysis: Delivers in-depth insights into market performance across key regions and countries, highlighting revenue trends, growth opportunities, and market potential.
Chapter 7 - Market Segmentation: Examines the market by type, identifying key segments, growth prospects, and high-opportunity areas.
Chapter 8 - Application Analysis: Explores major application areas, emerging demand trends, and sectors contributing to market expansion.
Chapter 9 - Supply Chain Analysis: Maps the end-to-end industry value chain, providing insights into upstream suppliers, downstream channels, and overall market structure.
Chapter 10 - Key Insights and Strategic Outlook: Summarizes the report with actionable insights, strategic recommendations, and growth opportunities to support future market planning.
Request a Customized Market Report Today:- https://www.datamintelligence.com/customize/niemann-pick-disease-type-c-market?kb
Niemann-Pick Disease Type C (NPC) Market Drivers
Growing Awareness and Early Diagnosis: Increased physician awareness, newborn screening initiatives, and improved genetic testing are enabling earlier diagnosis of NPC, driving demand for disease management and treatment.
Advancements in Gene and Targeted Therapies: Ongoing research into gene therapy, substrate reduction therapy, and novel disease-modifying treatments is expanding the therapeutic landscape for NPC.
Rising Investment in Rare Disease Research: Government funding, orphan drug incentives, and increased pharmaceutical investment are accelerating clinical trials and the development of innovative NPC therapies.
Supportive Regulatory Frameworks: Fast-track approvals, orphan drug designations, and regulatory incentives are encouraging biotechnology and pharmaceutical companies to develop treatments for Niemann-Pick Disease Type C.
FAQ
Q1: What is the current market size of the Niemann-Pick Disease Type C (NPC) Market and its future outlook?
Ans: The global Niemann-Pick Disease Type C (NPC) Market reached US$ 203.69 Million in 2025 and is forecast to attain US$ 1850.04 Million by 2035
Q2: How fast is the Niemann-Pick Disease Type C (NPC) Market expected to grow during the forecast period?
Ans: The market is projected to expand at a CAGR of 24.5% from 2026 to 2035, reflecting strong growth potential over the forecast period.
Q3: Which region leads the Niemann-Pick Disease Type C (NPC) Market?
Ans: North America accounted for the largest market share in 2025
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Niemann-Pick Disease Type C (NPC) Market Redefines Rare Disease Care with Emerging Treatment Strategies | United States Growth Expansion here
News-ID: 4591084 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Facade Materials Market Size, Share & Forecast 2032 | Industry Trends, Growth Op …
Market Size and Growth 2026
Global Facade Materials Market reached US$ 181.83 billion in 2024 and is expected to reach US$ 246.93 billion by 2032, growing with a CAGR of 3.9% during the forecast period 2025-2032.
Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/facade-materials-market?sb
DataM Intelligence has released a new research report titled Facade Materials Market Size 2026 The report delivers in-depth insights into key market dynamics, including…
EV Charging Infrastructure Market Size, Share, Industry, Forecast and Outlook (2 …
The global EV Charging Infrastructure market was valued at USD 56.85 billion in 2025 and is projected to reach USD 1,936.81 billion by 2035, expanding at a remarkable CAGR of 32.8% during the forecast period from 2026 to 2035. The market has emerged as one of the fastest-growing investment opportunities within the electric mobility and clean energy sectors, driven by accelerating electric vehicle (EV) adoption, large-scale government investments, and rapid…
E-Fuel Market Size, Share, Industry, Forecast and Outlook (2026-2033): Neste Cor …
The global E-Fuel market reached USD 13.24 billion in 2025 and is projected to reach USD 321.05 billion by 2033, expanding at a remarkable CAGR of 48.96% during the forecast period from 2026 to 2033. The market has emerged as one of the fastest-growing investment opportunities within the clean energy and sustainable fuels sector, driven by the global push toward decarbonization, increasing adoption of carbon-neutral transportation fuels, and supportive government…
United States Beauty Drinks Market 2035 | Growth Drivers, Trends & Market Foreca …
Market Size and Growth 2026
The Global Beauty Drinks Market size was valued at USD$ 2,172.36 million in 2025 to USD$ 2,446.08 million in 2026 and is projected to witness lucrative growth by reaching up to USD$ 7,114.77 million by 2035. The market is growing at a CAGR of 11.4% during the forecast period (2026-2035).
DataM Intelligence has released a new research report titled Beauty Drinks Market Size 2026 The…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
